Studies on PIVKA-X.
The incorporation of 14C-glucosamine and 3H-leucine into PIVKA-X and factor X has been studied in Macaca mulatta by means of a monospecific precipitating antiserum. No difference in the incorporation into PIVKA-X and factor X was found. The half-lives of PIVKA-X and factor X were similar (about 30-35 h and 27-31 h respectively) indicating that the vitamin K-induced modifications did not alter the survival of protein. A Russell's-viper venom/cephalin test system for factor X was more sensitive to inhibition by PIVKA-X than was a tissue thromboplastin-based system.
D000327:Adsorption; D000818:Animals; D001466:Barium Sulfate; D004355:Drug Stability; D005170:Factor X / Q000096:biosynthesis / Q000378:metabolism*; D005944:Glucosamine / Q000097:blood; D006207:Half-Life; D000882:Haplorhini; D007930:Leucine / Q000378:metabolism; D008253:Macaca mulatta; D010714:Phosphatidylethanolamines / Q000494:pharmacology; D011498:Protein Precursors / Q000096:biosynthesis / Q000378:metabolism*; D014812:Vitamin K / Q000502:physiology*; D014813:Vitamin K Deficiency / Q000097:blood; D014859:Warfarin / Q000494:pharmacology
D010714:Phosphatidylethanolamines; D011498:Protein Precursors; D014812:Vitamin K; D001466:Barium Sulfate; D014859:Warfarin; D005170:Factor X; D007930:Leucine; D005944:Glucosamine